Overview

Gilenya in Amyotrophic Lateral Sclerosis (ALS)

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether Gilenya, also known as fingolimod, is safe and tolerable in patients with Amyotrophic Lateral Sclerosis (ALS).

Phase:

Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

ALS Therapy Development Institute

Treatments:

Fingolimod Hydrochloride